ProText Mobility Inc (TXTM)

[DD_dempsey]

MUST READ Anaylsis on $TXTM

It is my opinion, that yesterday's news was purposeful but unfortunately resulted in a head fake for some- and was used by some by others as a last minute attempt to shake loose shares here at .0007 pps. HOWEVER - that news was actually quite useful and important.

Yestedsy's news serves to prove to shareholders that the major US University is obviously very connected and competent if they can identify areas to improve the drug quality, work with illicit drugs like cannabis legally and even submit drugs for FDA approval. The issue in America with Diabetes and Arthritis leaves millions debilitated. They are definitely looking for cannabinoid based solutions for these major US health issues and this is one way they are paying for the studies and process.
Anyone also notice that as pps increases - so too are the volume trends. That means considerable more money is being traded for shares here daily AND that's growing daily for a reason. The news that they put out in July followed by a specific tweet on Aug 1st suggests they are VERY CLOSE to getting the official Cannabis license. Yesterday's news helped serve the purpose of continued interest here- and shake any shares they could out at .0007 pps. This easily got bought up back to 9/10. I suspect we see a low now of .0008 pps and this could break into .001's pps as there appears to be NO MORE STEPS LEFT needed before this gets the license approval. See the breakdown analysis below:

Please read this part of the July press release again....

Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, "Following the submission of our license application earlier this year, officials from the Department Health inspected the company's facilities in May. The 10,000 square foot facility will be used to both grow and harvest the live cannabis and to produce a formulated cannabinoid complex. Our application and all supporting documents were reviewed by the Portfolio Committee during the first week of July, 2017. Subsequent to that review, the Department of Health requested additional details regarding production schematics, operational protocols and product distribution. The Company intends to submit these final requests this week and we believe that the license will be granted imminently."

NOW check the tweet out from TXTM-Plandai SA- on Aug 1- ALL FINAL DOCUMENTS submitted.

$TXTM - CEO, Roger Duffield, "Subsequently, all final documents requested by Ministry of Health have been submitted for license issuance."

— Protext Pharma, Inc ($TXTM) (@protxtm) August 1, 2017

Once the license is issued, Protext will commence setting up its grow facility where plants can be cloned and cultivated to ensure a consistent chemical profile. An on-site extraction laboratory will take the live plant material and produce a cannabis complex containing the full profile of all the phytonutrients, including cannabinoids, terepenes, cannabinoid acids and polyphenols. Based on parent-company Plandaí's clinically-proven science, the resulting complex is anticipated to contain the full profile of cannabinoids, including the precursor acids THC-A and THC-B together with CBD, in a non-psychoactive extract. Once the first plant extract is produced, it will be subjected to extensive chemical profiling in addition to tests to confirm its bioavailability, ability to cross the blood brain barrier, and lack of psycho-activity.

Mr. Duffield added, "After our application is issued, Protext will be one of a few companies in the world legally allowed to conduct research and development and produce cannabis medicines. Part of our business model will be working with the government of South Africa to develop cannabis medicines with an objective of having our extract declassified from a Level 6 controlled substance to a Level 0 controlled medicine, based on non-psychoactivity. This declassification should help facilitate our selling the product throughout the world."

HERE IS THE PART Of thr July PR- that mentions the work they are doing in coordination with a certain major US University legally empowered ...hmmmm.....to undertake cannabis research and submit application for a FDA approved cannabis drug. This jives with the news yesterday that they are now working hand in hand with the researchers at the US university to improve the delivery system.

"In the meantime, Protext is taking the necessary steps to align itself with a major U.S. University that is legally empowered to undertake cannabis medicines research, with the goal of eventually submitting an application for an FDA botanical drug claim. These defined studies will establish anti-inflammatory activities with cannabinoid receptors in order to develop Protext's non-psychoactive medicines for specific arthritis therapies. These investigations are intended to further establish the therapeutic benefits through the suppression and containment of inflammation in human cells and are expected to establish improved activity by the slowing of degradation in affected joints and the reduction of both pain and disability. Arthritis is the most common cause of disability in the US. More than 20 million individuals with arthritis have severe limitations in function on a daily basis. It is estimated that the total cost of arthritis cases is close to $100 billion of which almost 50% is from lost earnings. Each year, arthritis results in nearly 1 million hospitalizations and close to 45 million outpatient visits to health care centers. Our proposed cannabinoid anti-inflammatory drug has the potential to deliver products with lesser side effects and better efficacy over current drug regimens," concluded Mr. Duffield

IT IS MY STRONG OPINION, that $TXTM under Protext Pharma are now very very close to announcing significant worldwide news. The stock pps is now trending higher than it has been for weeks and for very good reason. I suspect we will see this continued volume and a strong break into the teens as more confirmations and validations continue that TXTM will effectively control the cannabis market in South Africa with the help of thr South African and US governments and via their soon to be issued license- an approval of delivery system for cannabinoids. ALSO Of major importance -- $TXTM will then apply for FDA approval of Cannabinoid delivery - a US patented and owned formation of the Cannabis plant.

IF I WERE MANAGEMENT Of $TXTM right now- I would not let this opportunity for increasing shareholder values and awareness go to waste. I would strongly encourage the management to put out MJ news relevant to their last update July 13th and Aug 1st. I would utilize all of the resources around me to get a formidable deal done and announced making it quite clear - the potential revenues to be enjoyed here because of how difficult it will be for other companies to GET THIS APPROVED LICENSE in SOUTH AFRICA.